TY - JOUR
T1 - Research Priorities for Patients with Heart Failure and Central Sleep Apnea An Official American Thoracic Society Research Statement
AU - on behalf of the American Thoracic Society Assembly on Sleep and Respiratory Neurobiology
AU - Orr, Jeremy E.
AU - Safwan Badr, M.
AU - Ayappa, Indu
AU - Eckert, Danny J.
AU - Feldman, Jack L.
AU - Jackson, Chandra L.
AU - Javaheri, Shahrokh
AU - Khayat, Rami N.
AU - Martin, Jennifer L.
AU - Mehra, Reena
AU - Naughton, Matthew T.
AU - Randerath, Winfried J.
AU - Sands, Scott A.
AU - Somers, Virend K.
N1 - Funding Information:
7National Institute of Environmental Health Sciences, NIH, Durham, North Carolina; 8Intramural Program, National Institute on Minority Health and Health Disparities, NIH, Bethesda, Maryland; 9Division of Pulmonary and Sleep Medicine, Bethesda North Hospital, Cincinnati, Ohio; 10Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio; 11University of California, Irvine, Sleep Disorders Center and 12Division of Pulmonary and Critical Care, University of California, Irvine, Irvine, California; 13The Sleep Heart Program, Ohio State University, Columbus, Ohio; 14Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; 15David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California;16Sleep Disorders Center, Neurological Institute, 17Respiratory Institute, 18Heart and Vascular Institute, and 19Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; 20Department of Respiratory Medicine, Alfred Hospital–Monash University, Melbourne, Victoria, Australia;21Institute of Pneumology, University of Cologne–Bethanien Hospital, Solingen, Germany; 22Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital–Harvard Medical School, Harvard University, Boston, Massachusetts; and 23Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota Author Disclosures: J.E.O. received a partnered grant from the ATS Foundation/ ResMed. I.A. received research support and royalties on continuous positive airway pressure titration patents from Fisher & Paykel. D.J.E. served as a consultant and on an advisory committee for Apnimed; received research support from Bayer and Oventus Medical; and received a senior research fellowship from the National Health and Medical Research Council of Australia. S.J. served as a consultant for Respicardia; and received research support from the NIH for a trial on LOFT-HF. R.N.K. served as a consultant for Respicardia; and served as a speaker for Philips Respironics. R.M. served on an advisory committee for the American Board of Internal Medicine, Merck, and Respicardia; served as a consultant for Respicardia; received research support from the American Heart Association, the NIH, Natus, Philips Respironics, and ResMed; and received royalties from UpToDate. W.J.R. served as a speaker for Bayer Vital, Berlin-Chemie, Bioprojet, Boehringer Ingelheim, Heinen & Löwenstein, Inspire, Novartis, Night Balance, Philips Respironics, ResMed, Vanda Pharma, and Weinman; and received research support from Heinen & Löwenstein and Philips Respironics. V.K.S. served as a consultant for Baker Tilly, Bayer, Jazz Pharmaceutical, GlaxoSmithKline, ResMed, Respicardia, and Roche; and received research support from the NIH, Philips Foundation, and Sleep Number. M.S.B., J.L.F., C.L.J., J.L.M., M.T.N., and S.A.S. reported no commercial or relevant noncommercial interests.
Funding Information:
Supported by the American Thoracic Society; the Intramural Program at the NIH, National Institute of Environmental Health Sciences (Z1A ES103325-01); NIH grant R01HL130552; and Veterans Health Administration Office of Research and Development grant I01CX001040.
Publisher Copyright:
Copyright © 2021 by the American Thoracic Society
PY - 2021/3/15
Y1 - 2021/3/15
N2 - Background: Central sleep apnea (CSA) is common among patients with heart failure and has been strongly linked to adverse outcomes. However, progress toward improving outcomes for such patients has been limited. The purpose of this official statement from the American Thoracic Society is to identify key areas to prioritize for future research regarding CSA in heart failure. Methods: An international multidisciplinary group with expertise in sleep medicine, pulmonary medicine, heart failure, clinical research, and health outcomes was convened. The group met at the American Thoracic Society 2019 International Conference to determine research priority areas. A statement summarizing the findings of the group was subsequently authored using input from all members. Results: The workgroup identified 11 specific research priorities in several key areas: 1) control of breathing and pathophysiology leading to CSA, 2) variability across individuals and over time, 3) techniques to examine CSA pathogenesis and outcomes, 4) impact of device and pharmacological treatment, and 5) implementing CSA treatment for all individuals Conclusions: Advancing care for patients with CSA in the context of heart failure will require progress in the arenas of translational (basic through clinical), epidemiological, and patient-centered outcome research. Given the increasing prevalence of heart failure and its associated substantial burden to individuals, society, and the healthcare system, targeted research to improve knowledge of CSA pathogenesis and treatment is a priority.
AB - Background: Central sleep apnea (CSA) is common among patients with heart failure and has been strongly linked to adverse outcomes. However, progress toward improving outcomes for such patients has been limited. The purpose of this official statement from the American Thoracic Society is to identify key areas to prioritize for future research regarding CSA in heart failure. Methods: An international multidisciplinary group with expertise in sleep medicine, pulmonary medicine, heart failure, clinical research, and health outcomes was convened. The group met at the American Thoracic Society 2019 International Conference to determine research priority areas. A statement summarizing the findings of the group was subsequently authored using input from all members. Results: The workgroup identified 11 specific research priorities in several key areas: 1) control of breathing and pathophysiology leading to CSA, 2) variability across individuals and over time, 3) techniques to examine CSA pathogenesis and outcomes, 4) impact of device and pharmacological treatment, and 5) implementing CSA treatment for all individuals Conclusions: Advancing care for patients with CSA in the context of heart failure will require progress in the arenas of translational (basic through clinical), epidemiological, and patient-centered outcome research. Given the increasing prevalence of heart failure and its associated substantial burden to individuals, society, and the healthcare system, targeted research to improve knowledge of CSA pathogenesis and treatment is a priority.
KW - Heart failure
KW - Respiration
KW - Sleep apnea
UR - http://www.scopus.com/inward/record.url?scp=85102628362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102628362&partnerID=8YFLogxK
U2 - 10.1164/rccm.202101-0190ST
DO - 10.1164/rccm.202101-0190ST
M3 - Article
C2 - 33719931
AN - SCOPUS:85102628362
SN - 1073-449X
VL - 203
SP - E11-E24
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 6
ER -